Outcomes of primary refractory multiple myeloma and the impact of novel therapies

Over the past decade, use of novel agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has resulted in high response rates and improvement in overall survival (OS) for patients with multiple myeloma (MM); however, the prognostic significance of refractoriness to these ag...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Am J Hematol
Main Authors: Majithia, Neil, Rajkumar, S. Vincent, Lacy, Martha Q., Buadi, Francis K., Dispenzieri, Angela, Gertz, Morie A., Hayman, Suzanne R., Dingli, David, Kapoor, Prashant, Hwa, Lisa, Lust, John A., Russell, Stephen J., Go, Ronald S., Kyle, Robert A., Kumar, Shaji K.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801545/
https://ncbi.nlm.nih.gov/pubmed/26214732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24131
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker